827,217 Shares in Genmab A/S Sponsored ADR $GMAB Bought by Perpetual Ltd
Perpetual Ltd purchased a new stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm...
MarketBeat·22h ago
More News
JPMorgan Chase & Co. Decreases Position in Genmab A/S Sponsored ADR $GMAB
JPMorgan Chase & Co. decreased its position in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 87.3% during the third quarter, according to the company in its most recent disclosure...
MarketBeat·1d ago
Arrowpoint Investment Partners Singapore Pte. Ltd. Takes Position in Genmab A/S Sponsored ADR $GMAB
Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new position in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) in the fourth quarter, according to its most recent filing...
MarketBeat·1d ago
Genmab A/S (OTCMKTS:GNMSF) Shares Gap Down - Here's Why
Genmab A/S (OTCMKTS:GNMSF) Shares Gap Down - Here's Why...
MarketBeat·5d ago
Terra Nova Asset Management LLC Invests $1.87 Million in Genmab A/S Sponsored ADR $GMAB
Terra Nova Asset Management LLC bought a new stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) during the 4th quarter, according to the company in its most recent Form 13F...
MarketBeat·7d ago
Genmab A/S (OTCMKTS:GNMSF) Short Interest Update
Genmab A/S (OTCMKTS:GNMSF - Get Free Report) saw a significant decrease in short interest in March. As of March 13th, there was short interest totaling 114,947 shares, a decrease of 20.8% from the...
MarketBeat·7d ago
Wolfe Research Begins Coverage on Genmab A/S (NASDAQ:GMAB)
Wolfe Research began coverage on shares of Genmab A/S in a research note on Friday. They issued an "outperform" rating and a $32.00 price objective for the company...
Genmab A/S (NASDAQ:GMAB) executives highlighted a very strong year in 2025 and outlined a catalyst-heavy 2026 that could set up multiple launches in 2027, according to remarks made by Chief Financial...
MarketBeat·18d ago
Genmab A/S Teases 2026 Wave of Registrational Readouts for EPKINLY, Rina-S and Petosemtamab
Genmab A/S (NASDAQ:GMAB) executives outlined a slate of late-stage clinical catalysts expected in 2026, highlighting multiple potentially registrational readouts across three key programs: EPKINLY...
MarketBeat·18d ago
Genmab A/S (OTCMKTS:GNMSF) Shares Gap Down - Time to Sell?
Genmab A/S (OTCMKTS:GNMSF) Shares Gap Down - Should You Sell...